{
    "text": "Therefore, the AKT inhibitor perifosine might potentially overcome the resistance to cisplatin-based chemotherapy in NSCLC patients with low-FHIT tumors, and consequently improve the outcome.", 
    "denotations": [
        {
            "id": "T1", 
            "obj": "gene", 
            "span": {
                "begin": 15, 
                "end": 18
            }
        }, 
        {
            "id": "T2", 
            "obj": "disease", 
            "span": {
                "begin": 117, 
                "end": 122
            }
        }
    ], 
    "relations": [
        {
            "id": "R1", 
            "pred": "therapeutic", 
            "subj": "T1", 
            "obj": "T2"
        }
    ]
}